Between now and 2030, somewhere between $200 billion and $400 billion in branded drug revenue walks off a cliff.

That’s not a forecast. It’s a calendar.

Keytruda. Eliquis. Stelara. Trulicity. Ibrance. Eylea. These are the financial engines of some of the largest companies in the world. And their patent clocks are already ticking.

Most brand teams know the date. They’ve modeled the revenue erosion. They’ve had the meetings.

But here’s what we keep seeing: the marketing plan for LOE doesn’t match the urgency of the math.

The legal team is working on patent extensions. BD is out looking for the next acquisition. R&D is building the next-gen formulation. The brand team? Often the last to get a real strategy. And they’re the ones responsible for what patients and HCPs actually experience.

That’s the gap this playbook is designed to close.

Why This Patent Cliff Is Different

We’ve seen patent cliffs before. The last major wave, roughly 2010 to 2014, was dominated by small molecules. Lipitor. Plavix. Seroquel. The playbook was straightforward, even if the losses were painful. Generics entered, prices dropped fast, and branded volume fell 80% to 89% within six months. You managed the decline or you got out of the way.

This cliff is different in three ways that matter for marketing.

It’s bigger.

Patent losses between 2025 and 2029 are projected to exceed $90 billion at net manufacturer prices. That’s more than in either of the last two five-year periods. Nearly 190 drugs are affected, 69 of them blockbusters generating over $1 billion annually.

It’s more complex.

This wave includes a significant number of biologics with unique delivery systems, administration pathways, and stability concerns. Biosimilar competition behaves differently than generic competition. Erosion is slower: 30% to 50% volume loss in the first year versus 80%+ for small molecules. But the strategic terrain is harder to navigate. Prescriber switching inertia is higher. Interchangeability designations add complexity. Payer formulary decisions create market-by-market variation that didn’t exist in the small-molecule era.

The policy landscape has shifted.

The Inflation Reduction Act adds a new pressure point. Brands like Keytruda face government pricing negotiations before LOE even hits. Revenue compression starts earlier, and the financial window for brand investment is tighter than it’s ever been.

For brand teams, the takeaway is simple: the old LOE playbook of waiting, managing the decline, and shifting resources to the next product doesn’t work when the decline starts earlier, moves differently, and affects products that are deeply embedded in clinical practice.

Start Two Years Out. Not Two Quarters.

The most common mistake we see? Brand teams treating LOE like a sunset. Something to wind down gracefully. Scale back the sales force. Reduce the marketing spend. Let the product run on fumes.

LOE demands the same intensity, the same cross-functional coordination, and the same marketing rigor as the day that product first went to market. Think of it as a launch, running in reverse.

The companies that retain meaningful brand value after patent expiry have one thing in common: they started their LOE marketing strategy at least two years before the date. And we’re talking specifically about the marketing strategy. The legal and lifecycle management work is usually well underway. The marketing plan is the one that’s behind.

That means rethinking the brand narrative, the channel mix, the HCP engagement model, and the patient support infrastructure while the product is still generating peak revenue. It feels counterintuitive to invest in a brand that’s approaching expiry. But that’s exactly when the investment matters most.

The Three Pillars of LOE Brand Protection

We think about LOE marketing in three layers. Each one operates on a different timeline and targets a different audience. They need to work together.

1. Protect the Prescriber Relationship

When generics or biosimilars enter, payer pressure to switch is immediate. But prescribers don’t switch on price alone. They switch on confidence. More specifically, they switch when the cost of staying on the branded product can’t be justified by a clear clinical or experiential difference.

The work here is about deepening the clinical narrative around your brand before the competitive noise starts. Invest in real-world evidence that reinforces the specific reasons prescribers chose your product in the first place. Create content that speaks to the clinical differentiators in ways that map directly to the patient populations and treatment decisions your HCPs are making every day.

For biologics specifically, the switching conversation is more nuanced. HCPs need to understand the differences in manufacturing, formulation, and delivery. And they need that understanding before the biosimilar rep walks in the door. If your brand team isn’t shaping that conversation 18 months out, someone else will shape it for you.

2. Build Patient Loyalty That Survives the Switch Pressure

Patients don’t think about patent expiry. They think about whether their medication works, whether they can afford it, and whether their experience with the brand gives them a reason to stay. The support program. The injection device. The refill process. That’s where loyalty lives.

The smartest LOE strategies build patient stickiness long before the generic enters. Copay card programs that reduce out-of-pocket costs to parity with generics. Enrollment and adherence programs that create a relationship between the patient and the brand. Direct-to-patient communication that keeps the branded product visible and accessible even when the pharmacy is pushing alternatives.

Pfizer did this with Lipitor. They launched their copay card program, authorized generic partnership, and CRM infrastructure during the 180-day exclusivity window before full generic competition hit. AbbVie shifted field force resources from Humira to next-generation products Rinvoq and Skyrizi two full years before biosimilar entry. Novartis extended its copay assistance for Gilenya through the LOE transition.

The pattern is consistent: the brands that retain share are the ones that made staying easier than switching.

3. Control the Brand Narrative Through the Transition

This is where most brand teams go quiet. And that’s exactly the wrong move.

When a product approaches LOE, there’s a natural instinct to reduce marketing spend and redirect budget to newer assets. But when the brand goes silent, generic and biosimilar manufacturers fill the narrative vacuum. Along with payer messaging. The story about your product becomes someone else’s to tell.

The brands that hold value through LOE keep showing up. They repackage clinical data. They invest in digital point-of-care engagement. They maintain HCP touchpoints through the transition with a focused, efficient content strategy that keeps the brand present and credible.

If you’re planning a next-generation product (a new formulation, a subQ version of an IV biologic, a new indication), the LOE period is where you set the stage. The brand equity you’ve built doesn’t disappear at patent expiry. But it erodes fast if you stop investing in it.

The Messy Middle of LOE

Here’s the part nobody wants to talk about.

LOE strategy is a coordination problem as much as a marketing problem. Legal is managing the patent estate. BD is evaluating acquisitions. Medical Affairs is running real-world studies. Market Access is renegotiating contracts. And the brand team is caught in the middle of all of it, trying to execute a marketing plan that depends on decisions being made in five other functions.

This is where brands stall. A creative brief waits three weeks for legal review. MLR timelines push a campaign past the window where it would have mattered. The field force restructuring happens before the marketing transition is ready. The strategy was solid. The space between strategy and execution is where it fell apart.

We call this the messy middle. And brand teams facing LOE need an agency partner that operates there. One that understands the regulatory constraints, moves at the speed of the business, and can execute without the ramp-up time that most agencies require to get smart on your category.

What to Do Right Now

If your brand is 18 to 24 months from LOE and you don’t have a dedicated marketing strategy in place, start here.

Audit your brand equity. What do HCPs and patients actually believe about your product today? If you can’t articulate the specific clinical and experiential reasons someone would stay on your brand when a cheaper option appears, you have a messaging gap that needs to close before LOE hits.

Map the switching triggers. Understand where in the prescription flow the decision to switch happens. Is it at the payer level? The pharmacy level? The prescriber level? Each trigger point requires a different intervention, and most brand teams are only planning for one.

Build your patient retention infrastructure now. Copay programs, adherence tools, direct-to-patient communications, enrollment platforms. These take time to build and longer to drive adoption. If you launch them at LOE, you’re already behind.

Invest in content that carries your clinical differentiators. Real-world evidence. Patient experience data. Updated clinical narratives. These are the assets your field team and your digital channels need to keep the branded story alive through the transition.

Align with an agency that doesn’t need a ramp-up. LOE timelines don’t flex. You need a team that already understands your regulatory landscape, your MLR process, and the competitive dynamics of your category. One that can start executing before the window closes.

The Bottom Line

LOE is the moment that reveals whether the brand was built to last or built to sell.

The products that retain meaningful value after patent expiry are the ones where the brand team treated LOE with the same strategic intensity as launch. The marketing plan started two years early. The patient infrastructure was already in place. The clinical narrative was sharp enough to survive the noise of generic entry.

The patent cliff is coming.

The question is whether your marketing is ready to fight for what’s still worth keeping.